The effect of abaloparatide on the proximal femur in men with osteoporosis assessed by three-dimensional dual-energy X-ray absorptiometry.

Dhaliwal R, Boxberger J, Wang Y, Mitlak BH, Humbert L, Binkley N

JBMR plus5 Jun 2025Cited by 1 (Europe PMC)

PMID40692760PMCIDPMC12278270DOI10.1093/jbmrpl/ziaf098PepBankPUB-40692760

Summary

Abaloparatide treatment significantly increased BMD at the LS, TH, and FN compared with placebo in men with osteoporosis in the phase 3 ATOM trial. The current study used 3D-DXA modeling to evaluate the effects of abaloparatide on cortical and trabecular compartments of the proximal femur in ATOM study participants. Proximal femur DXA images were retrospectively analyzed using 3D-DXA (3D-Shaper software v2.12.0, 3D-Shaper Medical, Barcelona, Spain) to evaluate changes in bone parameters from baseline at months 6 and 12 in all randomized men from the ATOM trial. Between-group comparisons were made for percent change from baseline data based on a mixed-effect repeated-measure model with treatment, visit, treatment-by-visit interaction, and type of DXA scanner as fixed effects. Other covariates include BMI, age, and baseline values of bone parameters. Abaloparatide treatment significantly increased integral volumetric BMD (vBMD) (3.7%), trabecular vBMD (7.0%), cortical thickness (1.1%), and cortical surface BMD (1.7%) at 12 mo compared to baseline (p < .0001). Changes were greater for abaloparatide compared to placebo for all 4 parameters (p < .01). Significant increases from baseline compared to placebo in integral vBMD (2.7% vs -0.1%, p < .0001) and trabecular vBMD (6.1% vs -0.6%, p < .0001) were also observed at 6 mo. In conclusion, in men with osteoporosis, abaloparatide improved proximal femur 3D-DXA parameters broadly consistent with results in postmenopausal women in the ACTIVE study, adding to the growing data on abaloparatide bone structure effects at the hip.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, abaloparatide increased integral volumetric BMD by 3.7% from baseline, with greater change than placebo.
In plain wordsIn men with osteoporosis, abaloparatide increased whole bone density more than placebo at 12 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseIntegral volumetric BMD at 12 months
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Integral vBMD change
3.7%
abaloparatide at 12 months versus baseline
Source sentences
Summary
Abaloparatide treatment significantly increased integral volumetric BMD (vBMD) (3.7%), trabecular vBMD (7.0%), cortical thickness (1.1%), and cortical surface BMD (1.7%) at 12 mo compared to baseline (p < .0001).
3 context sentences(design, population, supporting numbers)
Summary · context
Changes were greater for abaloparatide compared to placebo for all 4 parameters (p < .01).
Summary · context
Proximal femur DXA images were retrospectively analyzed using 3D-DXA (3D-Shaper software v2.12.0, 3D-Shaper Medical, Barcelona, Spain) to evaluate changes in bone parameters from baseline at months 6 and 12 in all randomized men from the ATOM trial.
Summary · context
Between-group comparisons were made for percent change from baseline data based on a mixed-effect repeated-measure model with treatment, visit, treatment-by-visit interaction, and type of DXA scanner as fixed effects.
Show in the study text Report a problemFND-4069276001
02HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, abaloparatide increased trabecular volumetric BMD by 7.0% from baseline, with greater change than placebo.
In plain wordsIn men with osteoporosis, abaloparatide increased spongy bone density more than placebo at 12 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular volumetric BMD at 12 months
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Trabecular vBMD change
7%
abaloparatide at 12 months versus baseline
Source sentences
Summary
Abaloparatide treatment significantly increased integral volumetric BMD (vBMD) (3.7%), trabecular vBMD (7.0%), cortical thickness (1.1%), and cortical surface BMD (1.7%) at 12 mo compared to baseline (p < .0001).
3 context sentences(design, population, supporting numbers)
Summary · context
Changes were greater for abaloparatide compared to placebo for all 4 parameters (p < .01).
Summary · context
Proximal femur DXA images were retrospectively analyzed using 3D-DXA (3D-Shaper software v2.12.0, 3D-Shaper Medical, Barcelona, Spain) to evaluate changes in bone parameters from baseline at months 6 and 12 in all randomized men from the ATOM trial.
Summary · context
Between-group comparisons were made for percent change from baseline data based on a mixed-effect repeated-measure model with treatment, visit, treatment-by-visit interaction, and type of DXA scanner as fixed effects.
Show in the study text Report a problemFND-4069276002
03HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, abaloparatide increased cortical thickness by 1.1% from baseline, with greater change than placebo.
In plain wordsIn men with osteoporosis, abaloparatide increased outer bone thickness more than placebo at 12 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical thickness at 12 months
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Cortical thickness change
1.1%
abaloparatide at 12 months versus baseline
Source sentences
Summary
Abaloparatide treatment significantly increased integral volumetric BMD (vBMD) (3.7%), trabecular vBMD (7.0%), cortical thickness (1.1%), and cortical surface BMD (1.7%) at 12 mo compared to baseline (p < .0001).
3 context sentences(design, population, supporting numbers)
Summary · context
Changes were greater for abaloparatide compared to placebo for all 4 parameters (p < .01).
Summary · context
Proximal femur DXA images were retrospectively analyzed using 3D-DXA (3D-Shaper software v2.12.0, 3D-Shaper Medical, Barcelona, Spain) to evaluate changes in bone parameters from baseline at months 6 and 12 in all randomized men from the ATOM trial.
Summary · context
Between-group comparisons were made for percent change from baseline data based on a mixed-effect repeated-measure model with treatment, visit, treatment-by-visit interaction, and type of DXA scanner as fixed effects.
Show in the study text Report a problemFND-4069276003
04HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, abaloparatide increased cortical surface BMD by 1.7% from baseline, with greater change than placebo.
In plain wordsIn men with osteoporosis, abaloparatide increased outer bone surface density more than placebo at 12 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical surface BMD at 12 months
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Cortical surface BMD change
1.7%
abaloparatide at 12 months versus baseline
Source sentences
Summary
Abaloparatide treatment significantly increased integral volumetric BMD (vBMD) (3.7%), trabecular vBMD (7.0%), cortical thickness (1.1%), and cortical surface BMD (1.7%) at 12 mo compared to baseline (p < .0001).
3 context sentences(design, population, supporting numbers)
Summary · context
Changes were greater for abaloparatide compared to placebo for all 4 parameters (p < .01).
Summary · context
Proximal femur DXA images were retrospectively analyzed using 3D-DXA (3D-Shaper software v2.12.0, 3D-Shaper Medical, Barcelona, Spain) to evaluate changes in bone parameters from baseline at months 6 and 12 in all randomized men from the ATOM trial.
Summary · context
Between-group comparisons were made for percent change from baseline data based on a mixed-effect repeated-measure model with treatment, visit, treatment-by-visit interaction, and type of DXA scanner as fixed effects.
Show in the study text Report a problemFND-4069276004
05HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, integral volumetric BMD increased 2.7% with abaloparatide versus -0.1% with placebo at 6 months.
In plain wordsIn men with osteoporosis, abaloparatide increased whole bone density more than placebo at 6 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseIntegral volumetric BMD at 6 months
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Integral vBMD change
2.7%
abaloparatide at 6 months
Integral vBMD change
−0.1%
placebo at 6 months
Source sentences
Summary
Significant increases from baseline compared to placebo in integral vBMD (2.7% vs -0.1%, p < .0001) and trabecular vBMD (6.1% vs -0.6%, p < .0001) were also observed at 6 mo.
2 context sentences(design, population, supporting numbers)
Summary · context
Proximal femur DXA images were retrospectively analyzed using 3D-DXA (3D-Shaper software v2.12.0, 3D-Shaper Medical, Barcelona, Spain) to evaluate changes in bone parameters from baseline at months 6 and 12 in all randomized men from the ATOM trial.
Summary · context
Between-group comparisons were made for percent change from baseline data based on a mixed-effect repeated-measure model with treatment, visit, treatment-by-visit interaction, and type of DXA scanner as fixed effects.
Show in the study text Report a problemFND-4069276005
06HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, trabecular volumetric BMD increased 6.1% with abaloparatide versus -0.6% with placebo at 6 months.
In plain wordsIn men with osteoporosis, abaloparatide increased spongy bone density more than placebo at 6 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular volumetric BMD at 6 months
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Trabecular vBMD change
6.1%
abaloparatide at 6 months
Trabecular vBMD change
−0.6%
placebo at 6 months
Source sentences
Summary
Significant increases from baseline compared to placebo in integral vBMD (2.7% vs -0.1%, p < .0001) and trabecular vBMD (6.1% vs -0.6%, p < .0001) were also observed at 6 mo.
2 context sentences(design, population, supporting numbers)
Summary · context
Proximal femur DXA images were retrospectively analyzed using 3D-DXA (3D-Shaper software v2.12.0, 3D-Shaper Medical, Barcelona, Spain) to evaluate changes in bone parameters from baseline at months 6 and 12 in all randomized men from the ATOM trial.
Summary · context
Between-group comparisons were made for percent change from baseline data based on a mixed-effect repeated-measure model with treatment, visit, treatment-by-visit interaction, and type of DXA scanner as fixed effects.
Show in the study text Report a problemFND-4069276006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.